인간 면역결핍 바이러스 및 만성 B형 간염 바이러스 감염을 앓고 있는 참가자의 베피로비르센 연구(B-Focus) (B-Focus)
항레트로바이러스 치료 시 인간 면역결핍 바이러스 및 만성 B형 간염 바이러스 감염을 앓고 있는 참가자를 대상으로 베피로비르센 치료의 유효성 및 안전성을 평가하기 위한 다기관, 무작위, 이중 맹검, 위약 대조 연구
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Ekurhuleni, 남아프리카, 1459
- GSK Investigational Site
-
Johannesburg, 남아프리카, 2092
- GSK Investigational Site
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, 남아프리카, 4052
- GSK Investigational Site
-
-
-
-
-
Banchiau Taipei, 대만, 220
- GSK Investigational Site
-
Kaohsiung City, 대만, 813
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, 미국, 93301
- GSK Investigational Site
-
San Francisco, California, 미국, 94115
- GSK Investigational Site
-
-
Florida
-
Orlando, Florida, 미국, 32803-1851
- GSK Investigational Site
-
West Palm Beach, Florida, 미국, 33409
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55415
- GSK Investigational Site
-
-
New Jersey
-
Hillsborough, New Jersey, 미국, 08844
- GSK Investigational Site
-
-
-
-
-
Aracaju, 브라질, 49060-010
- GSK Investigational Site
-
Campinas, 브라질, 13034-685
- GSK Investigational Site
-
Curitiba, 브라질, 80810-050
- GSK Investigational Site
-
Manaus, 브라질, 69040-000
- GSK Investigational Site
-
Salvador, 브라질, 40110-060
- GSK Investigational Site
-
São Paulo, 브라질, 04121-000
- GSK Investigational Site
-
-
-
-
-
Barcelona, 스페인, 08036
- GSK Investigational Site
-
Córdoba, 스페인, 14004
- GSK Investigational Site
-
Madrid, 스페인, 28041
- GSK Investigational Site
-
Madrid, 스페인, 28040
- GSK Investigational Site
-
Madrid, 스페인, 28046
- GSK Investigational Site
-
Madrid, 스페인, 28031
- GSK Investigational Site
-
-
-
-
-
Almagro, 아르헨티나, C1427CEA
- GSK Investigational Site
-
Buenos Aires, 아르헨티나, 1023
- GSK Investigational Site
-
Buenos Aires, 아르헨티나, C1425AGC
- GSK Investigational Site
-
Buenos Aires, 아르헨티나, C1181ACI
- GSK Investigational Site
-
La Plata, 아르헨티나, B1900AVG
- GSK Investigational Site
-
Rosario, 아르헨티나, S2002KDR
- GSK Investigational Site
-
-
-
-
-
Bristol Avon, 영국, BS10 5NB
- GSK Investigational Site
-
London, 영국, E1 1BB
- GSK Investigational Site
-
London, 영국, SE5 9RS
- GSK Investigational Site
-
London, 영국, NW3 2QG
- GSK Investigational Site
-
-
-
-
-
Genova, 이탈리아, 16132
- GSK Investigational Site
-
Milan, 이탈리아, 20157
- GSK Investigational Site
-
Milan, 이탈리아, 20162
- GSK Investigational Site
-
Naples, 이탈리아, 80131
- GSK Investigational Site
-
Roma, 이탈리아, 00153
- GSK Investigational Site
-
Sassari, 이탈리아, 07100
- GSK Investigational Site
-
-
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, 캐나다, M5G 1K2
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2L 4P9
- GSK Investigational Site
-
Montreal, Quebec, 캐나다, H4A 3J1
- GSK Investigational Site
-
Québec, Quebec, 캐나다, G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Marseille, 프랑스, 13003
- GSK Investigational Site
-
Melun, 프랑스, 77000
- GSK Investigational Site
-
Montpellier, 프랑스, 34295
- GSK Investigational Site
-
Nantes, 프랑스, 44093
- GSK Investigational Site
-
Paris, 프랑스, 75018
- GSK Investigational Site
-
Paris, 프랑스, 75012
- GSK Investigational Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Documented chronic hepatitis B virus (HBV) infection and documented human immunodeficiency virus (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
-
Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.
o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).
-
Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
-
Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 international units per milliliter (IU/mL).
-
Plasma or serum HBsAg concentration >100 IU/mL and <=3000 IU/mL.
-
Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA <50 copies/mL.
-
Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm^3).
-
Alanine aminotransferase (ALT) <=2 times upper limit of normal (ULN).
Exclusion Criteria:
-
History of or suspected liver cirrhosis and/or evidence of cirrhosis.
-
Diagnosed or suspected hepatocellular carcinoma (HCC).
-
History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
-
Coinfection with:
-
Hepatitis C virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.
I. HCV treatment should have completed >12 months prior to Screening.
-
Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
-
-
Clinically significant abnormalities, aside from HIV-1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
-
Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
-
History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
-
History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
-
Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
-
Alcohol or drug abuse/dependence
-
Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
-
Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is contraindicated should not be considered for enrolment in the study.
-
Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
-
Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti platelet agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
-
Prior treatment with bepirovirsen.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Participants receiving Bepirovirsen
Participants will receive bepirovirsen. |
Bepirovirsen will be administered. |
|
위약 비교기: Participants receiving Placebo
Participants will receive placebo. |
Placebo will be administered. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
기간: At study week 60
|
HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (<) lower limit of quantification (LLOQ). |
At study week 60
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication
기간: At study week 24
|
HBV virologic response defined as HBsAg not detected and HBV DNA <LLOQ. |
At study week 24
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: GSK Clinical Trials, GlaxoSmithKline
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 219231
- 2023-509588-25 (기타 식별자: EU CT Number)
- 2023 (미국 NIH 보조금/계약)
- 2023-509588-25-00 (레지스트리 식별자: CTIS (EU))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 공유 기간
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 공유 액세스 기준
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .